Home

John Canan

CIK 1374366 · Sr.V-P Finc-Global Controller · last filed 2026-02-04

John Canan is a Sr.V-P Finc-Global Controller who has filed 42 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for TEX, was dated Feb 4, 2026. Across all open-market trades the lifetime net is −$1.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.5M across reported positions. 17 SEC filings were submitted jointly with Merck & Co., Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$6.47M

Companies

4

Total Filings

42

Lifetime Open-Market Net

-$1.83M

Filer Profile

Reported Address
C/O REV GROUP, INC.
111 EAST KILBOURN AVENUE, SUITE 2600
MILWAUKEE, WI 53202
Related Filers
Merck & Co., Inc. — 17 joint filings, latest 2014-02-26
MERCK SHARP & DOHME LLC — 12 joint filings, latest 2009-11-04
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TEX Director 62,076 $63.23 $3.93M $0 1 2026-02-04
REV Group, Inc. (REVG) Delisted Director 2,105 $63.90 $134.5K $80.8K 12 2026-02-02
Grace Therapeutics, Inc. (ACST) Delisted Director — $3.37 — $0 2 2022-09-30
MRK Sr.V-P Finc-Global Controller 16,955 $150.33 $2.55M -$1.91M 27 2014-02-26

Recent Filings

42 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-04 TEX Grant (A) +64,456 $0 EDGAR
2026-02-02 REV Group, Inc. (REVG) Delisted Disp (D) −65,390 $0 EDGAR
2025-12-05 REV Group, Inc. (REVG) Delisted Grant (A) +2,105 $0 EDGAR
2024-12-09 REV Group, Inc. (REVG) Delisted Grant (A) +3,611 $0 EDGAR
2023-12-12 REV Group, Inc. (REVG) Delisted Grant (A) +7,084 $0 EDGAR
2022-12-12 REV Group, Inc. (REVG) Delisted Grant (A) +7,960 $0 EDGAR
2022-09-30 Grace Therapeutics, Inc. (ACST) Delisted Grant (A) — $0 EDGAR
2021-12-13 REV Group, Inc. (REVG) Delisted Grant (A) +5,945 $0 EDGAR
2021-11-16 Grace Therapeutics, Inc. (ACST) Delisted Grant (A) — $0 EDGAR
2020-12-15 REV Group, Inc. (REVG) Delisted Grant (A) +10,584 $0 EDGAR
Showing 1–10 of 42
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.